Exagen Inc. (XGN) Misses Q2 EPS by 21c; Lowers Outlook

Exagen Inc. (NASDAQ: XGN) reported Q2 EPS of ($0.78), $0.21 worse than the analyst estimate of ($0.57). Revenue for the quarter came in at $9 million versus the consensus estimate of $12.03 million.

GUIDANCE:

Exagen Inc. sees Q3 2022 revenue of $35-40 million, versus the consensus of $53.35 million.

For earnings history and earnings-related data on Exagen Inc. (XGN) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Oracle (ORCL) Tops Q4 EPS by 16c, Offers Guidance
• Driven Brands (DRVN) Tops Q4 EPS by 2c, Misses on Revenue; Offers FY26 Guidance